Imricor Targets 250+ US Children’s Hospitals With Pediatric FDA Submission
Imricor targets US children’s hospitals with NorthStar pediatric FDA submission
Imricor Medical Systems (ASX: IMR) has submitted its NorthStar Mapping System to the US Food and Drug Administration for pediatric label expansion via the Special 510(k) pathway. The submission follows adult FDA clearance announced in January 2026 and targets clearance in the current quarter. Over 250 children’s hospitals across the United States represent the addressable market for this expansion.
The Imricor NorthStar Pediatric FDA Submission represents a second regulatory milestone within months of adult clearance, demonstrating execution pace on the company’s US commercialisation strategy. Pediatric expansion opens an entirely new customer segment before the broader adult market rollout begins, positioning the company to generate early revenue whilst building technology awareness across the interventional MRI market.
When big ASX news breaks, our subscribers know first
Why children’s hospitals matter for NorthStar adoption
Children’s hospitals have emerged as a strategic early channel for NorthStar adoption. These facilities have heightened interest in reducing radiation exposure for patients, creating strong alignment with the NorthStar system’s core value proposition.
As a navigation system for interventional cardiovascular magnetic resonance (iCMR) procedures, NorthStar eliminates x-ray fluoroscopy. The company has already received inbound interest from children’s hospitals following adult clearance and can currently sell to hospitals who have proactively contacted them. The pediatric submission aims to enable proactive marketing into this customer segment and support establishment of an installed base in pediatric centres during 2026.
The strategic advantages of the pediatric channel include:
- Strong alignment with radiation reduction priorities in children’s hospitals
- Inbound demand already demonstrated following adult clearance
- Generates early revenue ahead of adult hospital rollout
- Builds installed base and technology awareness across the interventional MRI sector
What is interventional MRI guidance?
Interventional MRI (iMR) represents a navigation approach for cardiovascular procedures that uses real-time magnetic resonance imaging instead of traditional x-ray fluoroscopy. MRI offers superior soft tissue imaging without ionising radiation, eliminating cumulative radiation exposure during procedures.
This distinction matters particularly for pediatric patients, who are more sensitive to radiation exposure over their lifetime. The technology addresses a genuine clinical need by providing high-quality imaging guidance whilst removing radiation risk entirely, which strengthens adoption potential amongst children’s hospitals and positions the system for broader market acceptance as awareness grows.
Commercial strategy taking shape across multiple channels
The pediatric submission forms part of a broader multi-channel US commercialisation strategy. The company aims to establish an installed base in pediatric centres during 2026, with pediatric adoption intended to generate revenue, expand awareness of the technology, and position the company for the broader adult electrophysiology (EP) platform rollout.
Steve Wedan, Executive Chair, President, and CEO
“We are moving very quickly to translate regulatory progress into clinical adoption and commercial traction, and this submission reflects our strategy of opening multiple paths to market NorthStar in the U.S.”
The company’s regulatory progress in the United States is summarised below:
| Milestone | Status | Timeline |
|---|---|---|
| NorthStar adult FDA clearance | Cleared | January 2026 |
| NorthStar pediatric submission | Submitted | April 2026 |
| Pediatric clearance expected | Pending | Current quarter |
The pediatric market represents what the company describes as an attractive early commercial channel for NorthStar in advance of broader US adoption of the full EP platform in adult hospitals. NorthStar may be well suited to adapt and improve iCMR procedure workflows currently performed with only stock MRI system interfaces, according to the announcement.
If cleared, the pediatric label expansion would allow the company to proactively market NorthStar for use in pediatric cases, broadening the addressable market for the system and strengthening commercial momentum in the United States.
The next major ASX story will hit our subscribers first
What this means for investors
The submission highlights rapid regulatory execution following adult clearance, with pediatric expansion providing a near-term revenue opportunity whilst the broader adult EP platform rollout progresses. Establishing an early installed base in children’s hospitals positions the company to build awareness and demonstrate clinical utility before targeting the larger adult hospital market.
The company has positioned itself as a broader interventional MR company rather than solely an iCMR ablation company. This framing expands the addressable market beyond cardiac ablation procedures to encompass other interventional cardiovascular applications where MRI guidance offers clinical advantages over x-ray fluoroscopy.
Steve Wedan, Executive Chair, President, and CEO
“This submission highlights that we are not just an iCMR ablation company. We are, more broadly, an interventional MR company. We are iMR.”
Near-term catalysts for the company include:
- Pediatric FDA clearance expected in the current quarter
- Engagement with children’s hospitals underway following inbound interest
- Installed base build-out during 2026 across pediatric centres
- Continued progress towards broader adult EP platform rollout in US hospitals
The pediatric expansion represents a second regulatory approval pathway opening within months, demonstrating the company’s ability to execute on multiple fronts simultaneously whilst building commercial traction in the United States market.
Get Medical Device Breakthroughs Before the Market Reacts
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to access real-time alerts covering FDA approvals, clinical milestones, and commercialisation updates the moment they hit the market.